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Abstract Natalizumab is an approved medication for
highly active multiple sclerosis (MS). Progressive multifocal
leukoencephalopathy (PML) may occur as a severe side effect
of this drug. Here, we describe pathological and radiological
characteristics of immune reconstitution inflammatory syn-
drome (IRIS), which occurs in natalizumab-associated PML
after the cessation of therapy, and we differentiate it from
ongoing PML. Brain biopsy tissue and MRI scans from five
MS patients with natalizumab-associated PML were analyzed
and their histology compared with non-MS PML. Histology
showed an extensive CD8-dominated T cell infiltrate and
numerous macrophages within lesions, and in nondemyeli-
nated white and grey matter, in four out of five cases. Few or
no virally infected cells were found. This was indicative of
IRIS as known from HIV patients with PML. Outstandingly
high numbers of plasma cells were present as compared to
non-MS PML and typical MS lesions. MRI was compatible
with IRIS, revealing enlarging lesions with a band-like or
speckled contrast enhancement either at the lesion edge or
within lesions. Only the fifth patient showed typical PML
pathology, with low inflammation and high numbers of virally
infected cells. This patient showed a similar interval between
drug withdrawal and biopsy (3.5 months) to the rest of the
cohort (range 2.5–4 months). MRI could not differentiate
between PML-associated IRIS and ongoing PML. We
describe in detail the histopathology of IRIS in natalizumab-
associated PML. PML–IRIS, ongoing PML infection, and MS
exacerbation may be impossible to discern clinically alone.
MRI may provide some clues for distinguishing different
pathologies that can be differentiated histologically. In our
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individual cases, biopsy helped to clarify diagnoses in
natalizumab-associated PML.
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Introduction
Natalizumab is a humanized anti-alpha4-integrin antibody.
Binding of the antibody on T cells, B cells, and monocytes
inhibits the entry of inflammatory cells into the brain [4]. In
phase III studies, natalizumab has been shown to signifi-
cantly reduce the relapse rate as well as disability
progression, and was approved as therapy for active
relapsing–remitting multiple sclerosis (MS) [17]. However,
so far, 170 cases (June 2011) of therapy-associated pro-
gressive multifocal leukoencephalopathy (PML) have been
documented [24].
PML is an opportunistic viral brain disease caused by a
reactivation of latent JC virus (JCV) infection. This infection
is increasingly recognized in patients treated with mono-
clonal antibody therapies [1, 2]. Histologically, JCV leads to
a demyelinating disease with ground glass oligodendrocytes
(oligodendrocytes with viral nuclear inclusions), bizarre
astrocytes, and a low inflammatory infiltrate. Magnetic res-
onance imaging (MRI) typically presents with focal or
multifocal high signal abnormalities on T2-weighted ima-
ges, which become confluent and larger with progression of
the disease. The lesions are diffuse and mainly located in
subcortical areas that tend to involve U fibers. In general,
they do not enhance after contrast injection [22].
The overall PML risk for MS patients treated with natal-
izumab is about 1:1,000 [28]. Patients with preceding
immunosuppression, therapy duration [2 years, and pres-
ence of anti-JCV antibodies have the highest risk of
developing PML (8.3:1,000; [20]). MRI shows new lesions
typically in areas not previously affected by MS that may
present gadolinium enhancement [2]. The only known
effective therapy for PML is reconstituting the immune
system. Natalizumab therapy is therefore stopped. Elimina-
tion of the antibody can be accelerated by plasmapheresis or
immunoadsorption [8, 27]. However, patients regularly
develop an exacerbation of symptoms or enlarging lesions or
increased gadolinium enhancement on MRI, indicative of
immune reconstitution inflammatory syndrome (IRIS) [2].
IRIS describes a clinical worsening in patients with
opportunistic infections due to recovery of the immune
system. This syndrome is known from HIV patients
receiving highly active antiretroviral therapy (HAART).
The histopathological hallmark in HIV patients with PML
is an inflammatory lesion with a dense T cell infiltrate
dominated by CD8? cells and numerous macrophages
[15, 19, 25]. Within lesions, the JC virus may be detected,
but it may also be cleared [25].
We describe here the histological and MRI characteristics
of five MS patients with natalizumab-associated PML, and
compare histological results with non-MS PML cases.
Patients and methods
Patients
MS patients with natalizumab-associated PML
We investigated biopsy tissue from five MS patients who had
been treated with natalizumab for different periods of time
ranging from 13 to 40 infusions. In cases 1 [21] and 5,
natalizumab-associated PML was diagnosed before biopsy
by JCV polymerase chain reaction (PCR) in cerebrospinal
fluid (CSF). Patient 1 presented three months after PML
diagnosis and [8 weeks after the last plasma exchange
(PLEX)/immunoadsorption (IA) with an enlarging, faintly
gadolinium-enhancing lesion. He was clinically stable at this
time. Biopsy was performed to distinguish between re-
emerging PML, late development of PML-associated IRIS,
or a rebound of MS after cessation of natalizumab treatment.
Patient 5 was biopsied 3.5 months after the last natalizumab
infusion because of continuous clinical progression. This
patient had received immunosuppressive therapy with
cyclosporin (serum concentrations 50–100 ng/ml started
two months before biopsy) as well as repeated intravenous
methylprednisolone (6 9 500–1,000 mg for five days, last
infusion four days before biopsy) to combat suspected IRIS.
Gadolinium-enhancing as well as nonenhancing lesions
were present on MRI. Biopsy was performed to distinguish
between PML-associated IRIS or ongoing PML. PML was
suspected in cases 2–4, but CSF PCR for JCV was initially
negative. Thus, biopsies were performed to diagnose PML.
Results received after biopsy showed low CSF copy numbers
in case 3, but remained negative for patients 2 and 4. Biopsies
had been performed at different centers for diagnostic rea-
sons and were sent to the Department of Neuropathology
in Go¨ttingen for a second opinion. Specimens were sent
from Wu¨rzburg (Germany), Santander (Spain), Hamburg
(Germany), Basel (Switzerland), and Munich (Germany).
Stereotactically guided needle biopsies were performed in
three patients (patients 1, 4, and 5) and open biopsies in two
patients (2 and 3). We detected single JCV-positive cells by
either immunohistochemistry (IHC) or in situ hybridization
(ISH) in two cases (cases 2 ? 3). JCV infection in case 4 was
assumed due to positive JCV PCR from brain tissue
(9.31 9 104 Geq/ml, H. H. Hirsch, Institute for Medical
Microbiology, University of Basel; confirmation by
E. O. Major, NIH, Bethesda, MD, USA). Sequencing
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revealed a rearranged, noncoding control region, as is typical
for PML. Moreover, an intrathecal JCV-specific antibody
production was found, which argues in favor of the diagnosis
of PML. The characteristics of this patient have been pub-
lished without a detailed histological analysis [11]. IHC in
case 5 showed numerous JCV-infected cells. Clinical and
laboratory data are summarized in Table 1. Patients gave
written informed consent for participation in this study.
Follow-up of patients showed clinical stabilization in
patients 1 and 3. The Expanded Disability Status Score
(EDSS) in patient 1 was 4.0 and in patient 3 was 8.5 at
biopsy and last follow-up. Patients 2 and 4 showed clinical
improvement after biopsy (patient 2: EDSS at biopsy 8.0,
EDSS at last follow-up 6.5; patient 4: EDSS at biopsy 4.0,
EDSS at last follow-up 3.5). Unfortunately, patient 5
deteriorated steadily even after biopsy and was discharged
from hospital to a nursing home with an EDSS of 9.5
(EDSS at biopsy 5.5). Follow-up periods ranged between 6
and 27 months.
PML patients without natalizumab treatment
Four patients with low-inflammation PML not related to
natalizumab were considered controls. Previous diseases
were HIV in two cases, suspected mastocytosis or lym-
phoma, and CD4 T-cell deficiency of unknown etiology.
Diagnosis was confirmed by IHC for JCV. Moreover, three
cases of ‘‘inflammatory’’ PML, characterized by an unusu-
ally high inflammation, were included: (1) an HIV patient
initially published by Vendrely et al. [25]; this patient
developed an IRIS after PML and initiation of HAART
therapy (HIV–PML–IRIS); (2) a 67 year-old male patient
with rheumatoid arthritis as well as prostate cancer and
preceding chemotherapy; (3) a 62 year-old female without
previous illnesses. As there is currently no exact definition of
inflammatory PML, we used this term for patients with more
than 500 T cells/mm2 within PML lesions.
MS patients without PML
T cell and plasma cell numbers for MS plaques were taken
from the literature [13].
Histopathology
Immunohistochemistry
Specimens were fixed in 4% paraformaldehyde and
embedded in paraffin. Slices 4 lm thick were stained with
hematoxylin and eosin (HE), Luxol fast blue/periodic acid–
Schiff (LFB/PAS), and Bielschowsky’s silver impregna-
tion. Immunohistochemical staining was performed with a
biotin–avidin technique. The following primary antibodies
were used: anti-CD3 (clone CD3–12, Serotec, UK), anti-
CD8 (clone C8/144B, Dako, Denmark), anti-CD20 (clone
L26, Dako, Denmark), anti-CD138 (clone M/15, Dako,
Denmark), and for JCV detection anti-SV40 (clone
PAb416, Merck, Germany) and PAb 2003 (kindly provided
by Dr. R. J. Frisque, Pennsylvania State University, USA)
[16].
In situ hybridization
A JCV biotinylated probe corresponding to the entire JCV
genome was used for DNA–DNA ISH (Enzo Diagnostics,
Farmingdale, NY, USA).
Morphometry
The number of inflammatory cells and virally infected cells
(PAb2003) was counted in at least ten standardized
microscopic fields each of size 0.0625 mm2, defined by an
ocular morphometric grid. Demyelinated areas as well as
nondemyelinated white and grey matter were counted
separately. In the text and figures, the median number of
positive cells/mm2 is given.
Statistics
The nonparametric Spearman rank correlation test was
performed. Tests were classified as significant if the p value
was \0.05 (GraphPad Software, Inc., San Diego, CA,
USA).
MRI
Routine brain MRI using 1.5 or 3.0 T machines with the
standard protocol for MS was performed for the five
biopsied patients and consisted of the following scans:
axial dual fast spin-echo T2/proton density-weighted ima-
ges, spin echo T1-weighted images with and without
gadolinium contrast, and fluid inversion recovery (FLAIR)
scans. Acquisition parameters were not exactly the same in
all cases, as scans were performed in different centers. All
images were reviewed at the same reading center by expert
neuroradiologists (EWR, MAS).
Results
An extensive, CD8-dominated T cell infiltrate
was found in natalizumab-associated PML, indicative
of immune reconstitution inflammatory syndrome
Four out of the five analyzed biopsy cases showed a pro-
nounced inflammatory infiltrate. Of these, three patients
Acta Neuropathol (2012) 123:235–245 237
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showed brain tissue with inflammatory demyelinating
lesions (patients 1–3; Fig. 1a, b) and two displayed adja-
cent nondemyelinated white (patients 1 ? 4) or grey
matter (patients 2 ? 4); e.g., one patient (4) showed only
inflamed nondemyelinated white and grey matter.
The inflammatory demyelinating lesions showed a pro-
nounced T cell infiltrate (1,319 T cells/mm2, Fig. 1c) as
well as numerous macrophages. CD8? T cells dominated,
with the CD8/CD3 ratio ranging from 0.5 (patient 3) to 0.7
(patient 2) (Figs. 1d, 2). Nondemyelinated grey and white
matter presented a pronounced T cell infiltrate as well (grey
matter (GM): 315 T cells/mm2, white matter (WM): 819
cells/mm2; Fig. 1e, f).
Thus, histology—with pronounced, CD8-dominated
inflammation in lesions as well as nondemyelinated white
and grey matter—was compatible with IRIS as known from
HIV–PML–IRIS patients [15, 19, 25].
The fifth patient showed typical PML pathology, with
ground glass oligodendrocytes, bizarre astrocytes, high
numbers of virally infected cells, as well as a low inflam-
matory infiltrate.
MRI characteristics in natalizumab-associated PML
cases were compatible with IRIS
All patients showed T2 and FLAIR lesions characteristic of
MS that were nonenhancing after gadolinium application.
Moreover, all patients showed lesions compatible with
PML at the time point of first PML symptoms. These
lesions were enlarged and showed new or pronounced
gadolinium enhancement at biopsy 2.5–4 months later,
characterized as follows.
Patient 1 showed bilateral occipital, diffuse abnormali-
ties with little mass effect and fuzzy borders (Fig. 3a). T1
post-contrast images revealed hypointense lesions with
faint linear peripheral enhancement surrounding the lesions
(Fig. 3b, arrows).
Patient 2 revealed a large frontoparietal hyperintense
area with typical destruction of U fibers almost exclusively
confined to the white matter (Fig. 3c). The lesion was
hypointense in postcontrast T1-weighted images, with
some tiny, speckled enhancement at the lesion edge with-
out any mass effect (Fig. 3d, arrow).
Fig. 1 Histology of IRIS is
characterized by extensive
T-cell inflammation in
natalizumab-associated PML.
An inflammatory demyelinating
lesion with pronounced
inflammation is shown (a H&E,
b LFB/PAS). T cells are
dominated by CD8? T cells
(c CD3, d CD8). Inflammation
is also evident in adjacent
nondemyelinated white and
grey matter (e ? f CD3).
Original magnifications:
a ? b 940; c–f 9100.
Scale bars 200 lm. Patient 2
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An extensive lesion involving mainly the frontoparietal
region was observed in case #3 (Fig. 3e). The pattern of
enhancement in this case differed, as it showed intense
enhancement at the medial border and inside the lesion
(Fig. 3f, arrows), suggesting a diagnosis of IRIS.
A large, diffuse lesion in the parietooccipital area with
tiny, speckled enhancement within the lesion and linear
enhancement at the lesion edge was seen in patient #4 (not
shown).
The fifth patient with histologically confirmed, active
PML displayed multiple lesions, with the biopsied lesion
revealing linear and irregular gadolinium enhancement at
the lesion edge. Other lesions showed diffuse and speckled
enhancement within lesions (Fig. 4a, b).
In conclusion, MRI in patients with pronounced
inflammation shows different enhancement patterns with
(a) faint enhancement, located mainly in the periphery of
PML lesions (Fig. 3b), (b) linear and speckled enhance-
ment at the grey and white matter junction or within the
grey matter (Fig. 3d), and (c) intense focal or linear
enhancement inside PML lesions and in the periphery
(Fig. 3f). These characteristics are compatible with IRIS
[2]. However, as the fifth patient also showed MRI char-
acteristics compatible with PML-IRIS, MRI did not allow a
clear differentiation between PML and IRIS and active
PML.
Taking the histological and MRI results together, we
assume that the four analyzed cases with pronounced
inflammation (patients #1–4) represent the histopathology
of IRIS in natalizumab-associated PML (called MS–PML–
IRIS from here on).
MS–PML–IRIS showed pronounced T cell
inflammation compared with non-MS PML
and multiple sclerosis
In MS–PML–IRIS, the numbers of CD3-positive T cells as
well as CD8-positive T cells were approximately eight times
higher than in patients with PML not related to natalizumab
therapy (Fig. 2). Patients with inflammatory PML showed
high numbers of T cells, with the median reaching about
two-thirds of MS–PML–IRIS (Fig. 2). Comparing single
patients, case 3, with natalizumab-associated PML and
IRIS, showed a lower T-cell infiltrate (CD3? T cells: 435
cells/mm2) compared to the HIV–PML–IRIS patient (853
cells/mm2), indicating an overlap of MS–PML–IRIS and
inflammatory PML with respect to the T-cell inflammation.
Inflammatory cells were found in PML controls in grey
and nondemyelinating white matter as well (data not
shown).
T-cell numbers were compared with data from actively
demyelinating MS lesions from the literature [13]. T-cell
numbers in MS–PML–IRIS were nine times higher than in
MS controls, taking the published number of approxi-
mately 150 cells/mm2.
Outstandingly high numbers of plasma cells
in MS–PML–IRIS were evident
Strikingly high numbers of plasma cells were found in
lesions from patients with MS–PML–IRIS (Figs. 2, 5a). The
median was 752 plasma cells/mm2; thus, every third
inflammatory cell within the lesion represented a plasma
cell. Plasma cells were evenly distributed within the paren-
chyma. B cells were found predominantly in perivascular
spaces and in lower numbers (Fig. 2). Plasma cells were also
present in nondemyelinated white and grey matter (WM: 156
cells/mm2, GM: 41 cells/mm2; Fig. 5c, d).
In contrast, no plasma cells and B cells were found in
low-inflammatory PML not related to natalizumab therapy.
Inflammatory PML lesions showed 242 plasma cells/mm2;
thus, approximately every fifth inflammatory cell repre-
sented a plasma cell (Figs. 2, 5b). Comparing single
patients, plasma cells showed consistently higher values in
MS–PML–IRIS (lowest value 751 plasma cells/mm2)
compared to non-MS PML cases (highest value 320 plasma
cells/mm2).
In MS biopsies, approximately six plasma cells/mm2
were found within lesions [13]. Thus, plasma cell numbers
in MS–PML–IRIS were approximately 125 times higher
than in MS plaques.
Fig. 2 Quantification of inflammation and virally infected cells
within demyelinating lesions in MS–PML–IRIS, ongoing MS–PML,
and non-MS PML. Numbers of T cells (CD3), CD8? T cells (CD8),
B cells (CD20), plasma cells (CD138), and virally infected cells
(PAb2003) were analyzed within demyelinating lesions in MS–PML–
IRIS, ongoing MS–PML, and control groups. The median and range
are indicated
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Fig. 3 MRI characteristics of
patients with natalizumab-
associated PML and
histologically confirmed IRIS.
Axial FLAIR images (a, c, e) of
MS patients, cases 1, 2, and 3,
with corresponding contrast-
enhanced T1-weighted images
(b, d, f) are shown. Different
patterns of enhancement in IRIS
can be seen, ranging from faint
peripheral enhancement to
intense enhancement of the
lesions (open arrows in b, d,
and f). The area of biopsy is
indicated (closed arrows in a, c,
and e)
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MS–PML–IRIS showed no or low numbers of virally
infected cells
Single cells positive for JCV–DNA or protein were found
in two cases with MS–PML–IRIS (Fig. 2). Typical ground
glass oligodendrocytes at the lesion edge were not found.
In non-MS PML, virally infected cells were detected in
high numbers in lesions (Fig. 2), as well as in nondemye-
linated grey matter (45 PAb2003 ? cells/mm2, three cases)
and white matter (56 PAb2003 ? cells/mm2, two cases).
The inflammation correlated negatively with the number
of virally infected cells. This holds true for CD3? T cells
(Spearman r = -0.46, p = 0.03), CD8? T cells (r =
-0.53, p = 0.01), plasma cells (r = -0.45, p = 0.04), and
B cells (r = -0.43, p = 0.048).
Discussion
We describe in detail the histopathological features and
MRI correlates in five MS patients following natalizumab-
associated PML.
Our study was limited by the amount of tissue available
for investigations and the small number of patients
Fig. 4 MRI characteristics of a
patient with histologically
confirmed active natalizumab-
associated PML. Axial FLAIR
(a) and corresponding contrast-
enhanced T1-weighted images
(b) are shown (case 5). Linear
enhancement at the lesion edge
as well as diffuse and speckled
enhancement within lesions are
found (open arrows in b). The
enhancement pattern does not
allow differentiation between
active PML and IRIS. The
biopsied area is indicated
(closed arrow in a)
Fig. 5 High numbers of plasma
cells are evident in natalizumab-
associated PML with IRIS.
Strikingly high numbers of
plasma cells are found in MS–
PML–IRIS lesions (a). Lower
numbers are present in
inflammatory PML cases (b). In
MS–PML–IRIS, plasma cells
are also evident in
nondemyelinated white and
grey matter (c, d) (a–d CD138).
Original magnifications:
a–d 9100. Scale bars 200 lm.
a ? d Patient 2, b inflammatory
PML control, c patient 1
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investigated. Additionally, the different time frames
between the end of natalizumab treatment, diagnosis of
PML, CSF tests, and IRIS may affect the pathology of the
lesions, and must be taken into account when interpreting
the data. Nevertheless, the homogeneous pathology in four
out of five cases presented here gives a comprehensive
picture of MS–PML–IRIS.
Histology reveals strikingly pronounced inflammation
and no or only low numbers of virally infected cells in four
out of five patients, indicating a strong immune response.
The inflammation is dominated by CD8? T cells; the
abundance of plasma cells is remarkable. MRI shows
enlarging and gadolinium-enhancing lesions, compatible
with IRIS [2]. Thus, we interpret the histopathology dem-
onstrated here as PML-associated IRIS, as known from
HIV-associated PML [15, 19, 25]. However, inflammation
in our study is even more pronounced than in HIV–PML–
IRIS. This might be explained by the effectively reconsti-
tuted (and in MS patients otherwise intact) immune system
after the withdrawal of natalizumab. MS–PML–IRIS was
detectable in our analyzed patients even three months after
PLEX/IA, and also occurred in patient 2, who had received
neither of these therapies. IRIS typically occurs about
2–5 weeks after PLEX, necessitates repeated courses of
intravenous steroids (suggesting that IRIS persists for
several months), and has been described as occurring
without PLEX/IA three months after the withdrawal of
natalizumab [2, 23].
CD8? cytotoxic lymphocytes (CTLs) are known to be
the main effector cell in viral infection [6]. In PML, an
association between JC virus-specific CTLs and early
control of the disease was shown [3]. Moreover, CD4?
cells seem to play a critical role in viral defense. The
occurrence of PML in HIV patients with low CD4 counts
might be taken as an argument. JCV-specific CD4? T-cell
responses are found in PML survivors, but not in patients
with active PML [5].
A striking observation in our cases was the high number
of plasma cells in MS–PML–IRIS. Interestingly, natal-
izumab treatment increases circulating pre-B and B cells in
MS patients [10]. The mobilization of JCV carrying pre-B
cells from the bone marrow may play a role in natalizumab-
associated PML pathogenesis [14]. The role of plasma cells
for viral defense in PML is debated. On the one hand, as
PML develops despite the presence of JCV-specific
immunoglobulin G (IgG), the humoral immune response
seems incapable of preventing PML [9]. An intrathecal
synthesis of IgG-antibodies directed against the JCV viral
protein 1 (VP1) is found in 76% of PML patients, but is not
correlated with clinical outcome [26]. On the other hand, a
strong correlation between the plasma cell count in brain
tissue and the humoral intrathecal immune response to the
VP1 was found, suggesting a role for B cells/plasma cells
and JCV antibodies in PML [26]. Inflammatory PML
with extensive mononuclear inflammatory infiltrates,
including numerous plasma cells, was associated with a
less severe neurologic illness [18]. Finally, PML survivors
also showed significant increases in JCV-specific IgG
responses [7].
In summary, a specific cellular as well as humoral
immune response seems to be relevant for viral defense. In
our study, CD3- and CD8-positive T cells, B cells, as well
as plasma cells were negatively correlated with the number
of virally infected cells, underlining their potential role in
PML infection. We find higher plasma cell numbers in
MS–PML–IRIS patients than in non-MS inflammatory
PML cases, even when T-cell numbers are similar. Thus,
we cannot rule out the idea that a least part of the plasma
cell population is pre-existent and related to the natal-
izumab treatment.
The clinician who cares for an MS patient with PML
who is deteriorating clinically and radiologically after
stopping natalizumab therapy is faced with the differential
diagnosis of PML–IRIS, ongoing PML, and MS exacer-
bation. Histologically, in MS exacerbation, actively
demyelinating lesions that are otherwise typical of MS are
expected [12]. MRI is expected to show either homoge-
neously or ring-shaped enhancing lesions in typical
periventricular or subcortical localizations. The histologi-
cal characteristics of MS–PML–IRIS are clearly different
from typical PML, as found in our fifth patient with na-
talizumab-associated PML. This patient was treated with
immunosuppressive therapy before biopsy to combat IRIS.
This case demonstrates the difficulty involved in finding
the balance between suppressing clinical deterioration due
to PML–IRIS, which may even lead to death, and halting
the progression of PML [2]. Our patient with active PML
(patient 5) showed higher viral gene copies than the
patients with PML–IRIS histopathology (see Table 1).
However, paraclinical parameters such as CSF JC virus
load and peripheral CD4/CD8 cell counts do not help the
clinician, as increasing viral titers as well as normal CD4/
CD8 ratios can be found in both PML–IRIS and active
PML [2]. JC viral load is increased by greater than tenfold
in MS patients with PML–IRIS and early MRI gadolinium
enhancement [23]. Although it seems unlikely, we cannot
rule out that our patient with active PML showed IRIS
histopathology in nonbiopsied lesions. MRI shows
enlarging and gadolinium-enhancing lesions in both con-
ditions. Contrast enhancement is a nonspecific sign of an
impaired blood–brain barrier and can be seen with different
patterns in inflammatory conditions of the brain. So far, it
has not appeared possible to distinguish MS–PML–IRIS
from ongoing PML in MS patients using only imaging
data. However, PML lesions tend to show faint enhance-
ment in the periphery of the lesion. More cases with
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confirmed pathology are needed to identify MRI patterns
that differentiate these two entities.
In order to clarify the immunopathogenesis of MS–
PML–IRIS, further investigations should focus on the role
of plasma cells in JCV infection, as well as the effect of
natalizumab on immune surveillance and inflammation
within the CNS.
In summary, we report IRIS histopathology in four MS
patients with natalizumab-associated PML. Histopathology
is characterized by a pronounced inflammatory infiltrate with
a predominance of CD8? T cells and high numbers of
plasma cells within lesions as well as adjacent grey and white
matter. A biopsy was helpful in our cases to either establish
the diagnosis of PML infection or to differentiate between
ongoing PML, MS–PML–IRIS, and MS exacerbation. This
guided the clinician to either stop medication (steroids,
immunosuppressive therapy) in active PML or to further
suppress inflammation with steroids in MS–PML–IRIS.
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